DMW - Deutsche Medizinische Wochenschrift, Table of Contents Dtsch Med Wochenschr 2014; 139(S 02): S65-S69DOI: 10.1055/s-0033-1359993 Übersicht | Review article Diabetologie © Georg Thieme Verlag KG Stuttgart · New York Orale Add-on-Therapie zu Metformin bei Typ-2-Diabetes mellitus: Canagliflozin und Glimepirid im direkten Vergleich Oral add-on therapy to metformin in type 2 diabetes mellitus: A direct comparison beween canagliflozin and glimepiride J. Seufert 1 Abteilung Endokrinologie und Diabetologie, Klinik für Innere Medizin II, Universitätsklinikum Freiburg › Author Affiliations Recommend Article Abstract Buy Article Schlüsselwörter SchlüsselwörterSGLT-2-Inhibition - Canagliflozin - Typ-2-Diabetes - Glimepirid - viszerales Fettgewebe - Hypoglykämie Keywords KeywordsSGLT-2 inhibition - canagliflozin - type 2 diabetes - glimepiride - visceral adipose tissue - hypoglycaemia Full Text References Literatur 1 Amiel SA, Dixon T, Mann R et al. Hypoglycaemia in Type 2 diabetes. Diabet Med 2008; 25: 245-254 2 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie „Therapie des Typ-2-Diabetes“ – Langfassung.. 1. Auflage. Version 2. 2013. http://www.versorgungsleitlinien.de/themen/diabetes2/dm2_therapie/pdf/NVL-DM2-Ther-lang-2.pdf (letzter Zugriff 12.12.2013) 3 Cefalu WT, Leiter LA, Yoon KH et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013; 382: 941-950 4 DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009; 58: 773-795 5 Deshmukh AB, Patel MC, Mishra B. SGLT2 Inhibition: A Novel Prospective Strategy in Treatment of Diabetes Mellitus. Ren Fail 2013; 35: 566-572 6 Garber AJ. Hypoglycaemia: a therapeutic concern in type 2 diabetes. Lancet 2012; 379: 2215-2216 7 Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379 8 Roumie CL, Hung AM, Greevy RA et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: A cohort study. Ann Intern Med 2012; 157: 601-610 9 Seufert J. Kardiovaskuläre Endpunktstudien in der Therapie des Typ-2-Diabetes mellitus: Schlusswort. Dtsch Arztebl 2006; 103: A-1913 10 Signorovitch JE, Macaulay D, Diener M et al. Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non-insulin antidiabetes drugs. Diabetes Obes Metab 2013; 15: 335-341 11 Tschöpe D, Bramlage P, Binz C et al. Incidence and predictors of hypoglycaemia in type 2 diabetes – an analysis of the prospective DiaRegis registry. BMC Endocr Disord 2012; 12: 23 12 Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 2005; 28: 2948-2961
